Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: Results of the JALSG AML97 study

International Journal of Hematology

Volumn 91, Issue 2, 2010, Pages 284-292

  Sakamaki, Hisashi ^a   Miyawaki, Shuichi ^b   Ohtake, Shigeki ^c   Emi, Nobuhiko ^d   Yagasaki, Fumiharu ^e   Mitani, Kinuko ^f   Matsuda, Shin ^g   Kishimoto, Yuji ^h   Miyazaki, Yasushi ⁱ   Asou, Norio ^j   Takahashi, Masatomo ^k   Ogawa, Yoshiaki ^l   Honda, Sumihisa ^m   Ohno, Ryuzo ⁿ  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g Ohtanisinouchi Hospital   (Japan)

^h KANSAI MEDICAL UNIVERSITY   (Japan)

ⁱ NAGASAKI UNIVERSITY   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

^k ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l TOKAI UNIVERSITY   (Japan)

^m NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; AML; Post remission chemotherapy

Indexed keywords

CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FEMALE; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT CODING; PROSPECTIVE STUDY; SCORING SYSTEM; SIBLING; TISSUE TYPING;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77950917665     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0483-2     Document Type: Article

References (24)

1. R Ohno T Kobayashi M Tanimoto, et al. 1993 Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group Cancer 71 12 3888 3895 10.1002/1097-0142(19930615)71:12<3888::AID-CNCR2820711216>3. 0.CO;2-G 1:STN:280:DyaK3s3osVGjsw%3D%3D 8508355 (Pubitemid 23172966)
2. T Kobayashi S Miyawaki M Tanimoto, et al. 1996 Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group J Clin Oncol 14 1 204 213 1:CAS:528:DyaK28XhtVOjt7Y%3D 8558199 (Pubitemid 126424601)
3. S Miyawaki M Tanimoto T Kobayashi, et al. 1999 No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 70 2 97 104 1:CAS:528:DyaK1MXmsFersbw%3D 10497848
4. T Buchner W Hiddemann WE Berdel, et al. 2003 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group J Clin Oncol 21 24 4496 4504 10.1200/JCO.2003.02.133 14673036 (Pubitemid 46603514)
5. JO Moore SL George RK Dodge, et al. 2005 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 9 3420 3427 10.1182/blood-2004-08-2977 1:CAS:528:DC%2BD2MXjvFejsLs%3D 15572587 (Pubitemid 40628181)
6. RJ Mayer RB Davis CA Schiffer, et al. 1994 Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 14 896 903 10.1056/NEJM199410063311402 1:STN:280: DyaK2czlvFGluw%3D%3D 8078551 (Pubitemid 24299870)
7. PA Cassileth DP Harrington FR Appelbaum, et al. 1998 Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 23 1649 1656 10.1056/NEJM199812033392301 1:STN:280:DyaK1M%2FktFWktw%3D%3D 9834301 (Pubitemid 28550689)
8. JL Harousseau JY Cahn B Pignon, et al. 1997 Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 90 8 2978 2986 1:CAS:528:DyaK2sXms1CrtL0%3D 9376578
9. CD Bloomfield D Lawrence JC Byrd, et al. 1998 Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 18 4173 4179 1:CAS:528:DyaK1cXmtlCksLo%3D 9751631 (Pubitemid 28440576)
10. AK Burnett K Wheatley AH Goldstone, et al. 2002 The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial Br J Haematol 118 2 385 400 10.1046/j.1365-2141.2002.03724.x 12139722 (Pubitemid 34994639)
11. JC Byrd RK Dodge A Carroll, et al. 1999 Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered J Clin Oncol 17 12 3767 3775 1:STN:280:DC%2BD3c%2FksVymug%3D%3D 10577848
12. RF Schlenk A Benner F Hartmann, et al. 2003 Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial Leukemia 17 8 1521 1528 10.1038/sj.leu.2403009 1:CAS:528:DC%2BD3sXlslOitrY%3D 12886238 (Pubitemid 36986953)
13. S Suciu F Mandelli T de Witte, et al. 2003 Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial Blood 102 4 1232 1240 10.1182/blood-2002-12-3714 1:CAS:528:DC%2BD3sXmsFWksb8%3D 12714526 (Pubitemid 36988027)
14. Kuriyama K, Tomonaga M, Kobayashi T, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. Berlin: Springer; 1998. p. 901-5.
15. S Miyawaki H Sakamaki S Ohtake, et al. 2005 A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study Cancer 104 12 2726 2734 10.1002/cncr.21493 1:CAS:528:DC%2BD28XptlSktw%3D%3D 16284985 (Pubitemid 41799616)
16. E Kaplan P Meier 1958 Non parametric estimation from imcomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
17. S Keating T de Witte S Suciu, et al. 1998 The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Br J Haematol 102 5 1344 1353 10.1111/j.1365-2141.1998.896hm3674.x 1:STN:280:DyaK1cvitl2qsw%3D%3D 9753069
18. E Jourdan JM Boiron N Dastugue, et al. 2005 Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience J Clin Oncol 23 30 7676 7684 10.1200/JCO.2005.02.5940 16186596 (Pubitemid 46313268)
19. JJ Cornelissen WL van Putten LF Verdonck, et al. 2007 Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109 9 3658 3666 10.1182/blood-2006-06-025627 1:CAS:528:DC%2BD2sXkvFCitrs%3D 17213292 (Pubitemid 46641712)
20. M Yanada K Matsuo N Emi T Naoe 2005 Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis Cancer 103 8 1652 1658 10.1002/cncr.20945 15742336 (Pubitemid 40490026)
21. R Gray K Wheatley 1991 How to avoid bias when comparing bone marrow transplantation with chemotherapy Bone Marrow Transplant 7 Suppl 3 9 12 1855097
22. F Frassoni M Labopin E Gluckman, et al. 1996 Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time-a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT) Bone Marrow Transplant 17 1 13 18 1:STN:280:DyaK283nsVSktg%3D%3D 8673048 (Pubitemid 26031884)
23. A Bacigalupo MP Sormani T Lamparelli, et al. 2004 Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation Haematologica 89 10 1238 1247 15477210 (Pubitemid 39390450)
24. RF Schlenk K Dohner J Krauter, et al. 2008 Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 18 1909 1918 10.1056/NEJMoa074306 1:CAS:528:DC%2BD1cXlt1Ggu70%3D 18450602 (Pubitemid 351620111)